Meibomian gland dysfunction (MGD) is underdiagnosed and undertreated, with asymptomatic disease far more common than symptomatic disease. As the condition progresses, patients who were initially ...

TEL AVIV, Israel--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today ...

Please provide your email address to receive an email when new articles are posted on . With the exception of the eventual, however begrudging, acceptance of dry eye disease as a thing, the biggest ...

Please provide your email address to receive an email when new articles are posted on . The Systane iLux 2 meibomian gland dysfunction thermal pulsation system delivers heat and pressure therapy while ...

Dry eye disease is a condition that afflicts millions of people worldwide, causing constant discomfort and affecting their quality of life. One of the key culprits behind this condition is meibomian ...

TEL AVIV, Israel & MELBOURNE, Australia--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular ...

Label expansion for evaporative dry eye due to MGD will support further efforts to drive patient access to insurance-covered TearCare treatments MENLO PARK, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- ...

You’ve probably never heard of Meibomian Gland Dysfunction. But chances are, you may experience it at some point in your life. It’s something 69 News reporter Jaccii Farris knows firsthand. Over the ...

Meibomian gland dysfunction, an etiological factor of dry eye disease, showed promising results in response to treatment with intense pulsed light. A review published in Clinical Ophthalmology found ...

—AZR-MD-001 is a Potential First-in-Class Therapy Targeting Meibomian Gland Dysfunction (MGD), the Root Cause of Dry Eye Disease (DED) and Contact Lens Discomfort (CLD)— Azura Ophthalmics Ltd., a ...